Pharmaceuticals

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 10:32 4759

Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone

SIR-Spheres® new drug application is accepted by the National Medical Products  Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...

2020-11-26 01:17 1799

Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...

2020-11-25 08:27 2119

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...

2020-11-25 08:00 2268

RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferen...

2020-11-25 07:00 2581

Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare , the open innovation platform of Almirall, S.A. (ALM),  announces two new collaborations with theUniversity of South Australia and the Fundació Institut de Recerca de ...

2020-11-25 06:00 5570

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets

RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...

2020-11-25 04:38 1308

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose

MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...

2020-11-24 22:14 1353

New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials

Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials LONDON, Nov. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced t...

2020-11-24 16:05 7212

Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19

AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory inAuckland, New Zealand , has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after ...

2020-11-24 04:35 976

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL...

2020-11-23 21:28 9893

Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud

LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 /PRNewswire/ -- The Tony Blair Institute (TBI) and Oracle have brought cloud technology toAfrica to manage public health programs. Initially,Ghana, Rwanda, and Sierra Leone will use the newOracle Health Management System to create electronic health...

2020-11-23 21:05 4905

GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial

SEOUL, Nov. 23, 2020 /PRNewswire/ -- GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of lead candi...

2020-11-23 20:00 2046

Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition

BAD HOMBURG, Germany, Nov. 23, 2020 /PRNewswire/ -- Evidence indicates that omega-3 (ω-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health ca...

2020-11-23 19:00 1635

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2020-11-23 18:34 9273

Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China

SUZHOU, China and ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...

2020-11-23 18:32 1702

ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC

SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that positive clinical data based on a pre-p...

2020-11-23 09:30 3459

Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies

DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowle...

2020-11-23 09:00 2095

Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2020-11-23 08:00 5588

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today announced that the company was officially listed and it's shares commenced trading on the Main Board...

2020-11-20 21:09 12842
1 ... 141142143144145146147 ... 183